ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · EuroIntervention · 2026-09-21

Prespecified secondary analysis of SMART-CHOICE 3 (5,506 high-risk patients after PCI and DAPT): clopidogrel vs aspirin monotherapy reduced death, MI or stroke in females (4.3% vs 9.4%; HR 0.45) but not significantly in males (4.4% vs 6.0%); no sex interaction (p=0.288).

Secondary analysisn = 5,506
Kwon et al. Clopidogrel monotherapy versus aspirin monotherapy in females and males after percutaneous coronary intervention: a sex-stratified analysis of the SMART-CHOICE 3 trial
Cardiology · J Am Heart Assoc · 2026-08-20

Secondary analysis of OPT-BIRISK: in 4072 bleeding- and ischaemic-risk ACS patients with diabetes, 9 months of clopidogrel monotherapy vs clopidogrel plus aspirin cut BARC 2, 3 or 5 bleeding (2.1% vs 3.2%; HR 0.66) without more MACCE; consistent without diabetes.

Secondary analysisn = 7,758
Zhang et al. Clopidogrel Versus Dual-Antiplatelet Therapy for Long-Term Maintenance After Coronary Stenting in Ischemic and Bleeding Birisk Patients With Acute Coronary Syndromes and Diabetes: A Prespecified Subgroup Analysis of the OPT-BIRISK Trial

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.